Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer

Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer

BackgroundProgrammed death receptor-1 (PD-1) blockade shows little benefit in patients with microsatellite-stable colorectal cancer (MSS-CRC). Fruquintinib is a China-made anti-angiogenic drug which is approved for the third line therapy in mCRC. This study investigates the effect of the combination...

Full description

Bibliographic Details
Main Authors:	Qingli Li, Xiaojiao Cheng, Cong Zhou, Yao Tang, Fuli Li, Baiwen Zhang, Tinglei Huang, Jianzheng Wang, Shuiping Tu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-03-01
Series:	Frontiers in Oncology
Subjects:	fruquintinib sintilimab immunotherapy microsatellite stable colorectal cancer anti-angiogenesis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.841977/full

Similar Items

Efficacy and Safety of Fruquintinib Combined with Sintilimab in Treatment of Advanced Microsatellite Stable Colorectal Cancer
by: LI Shan, et al.
Published: (2023-12-01)

Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
by: Liying Sun, et al.
Published: (2021-10-01)

Case report: Durable response from tegafur/gimeracil/oteracil (S-1) combined with fruquintinib and sintilimab as a third-line treatment for MSS metastatic colorectal cancer with a BRAF V600E mutation
by: Chunxia He, et al.
Published: (2024-12-01)

Efficacy, safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer: A retrospective study
by: Weijie Zhang, et al.
Published: (2022-08-01)

Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)Research in context
by: Wensi Zhao, et al.
Published: (2023-12-01)

Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy
by: Kanglian Zheng, et al.
Published: (2024-08-01)

Clinical Progress of Fruquintinib in Colorectal Cancer: An Overview
by: Yejie Xie, et al.
Published: (2025-02-01)

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study
by: Ya-Ya Deng, et al.
Published: (2023-03-01)

Profile of Fruquintinib in the Management of Advanced Refractory Metastatic Colorectal Cancer: Design, Development and Potential Place in Therapy
by: Syaj S, et al.
Published: (2024-11-01)

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study
by: Caiyun Nie, et al.
Published: (2022-09-01)

Case Report: Severe Rashes Associated With Fruquintinib in a Patient With Metastatic Colorectal Cancer
by: Yefei Shu, et al.
Published: (2021-07-01)

Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
by: Rui-Hua Xu, et al.
Published: (2017-01-01)

Safety and efficacy of fruquintinib‐based therapy in patients with advanced or metastatic sarcoma
by: Chenliang Zhou, et al.
Published: (2024-07-01)

Effect of prognostic nutritional index on laboratory parameters and survival in metastatic colorectal cancer patients treated with fruquintinib: a retrospective study
by: Zeng Wang, et al.
Published: (2024-11-01)

Clinical Effect and Safety of PD-1 Inhibitors plus Fruquintinib as Later-line Treatment for Metastatic Colorectal Cancer
by: CHEN Lulu, ZHANG Liping, LI Jingwen, DONG Wenjie, WU Xin'ai
Published: (2023-06-01)

Raltitrexed, S-1 and fruquintinib (RSF) in the treatment of refractory metastatic colorectal cancer: study protocol for a multicenter, prospective, single-arm, phase II trial
by: Weibing Leng, et al.
Published: (2025-02-01)

Case report: Bullous pemphigoid associated with sintilimab therapy for pMMR/MSS colorectal cancer
by: Ting Wang, et al.
Published: (2023-03-01)

The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
by: Jianzheng Wang, et al.
Published: (2022-06-01)

Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies
by: Lei Wang, et al.
Published: (2020-11-01)

Validated UPLC-MS/MS method for quantification of fruquintinib in rat plasma and its application to pharmacokinetic study
by: Mei YB, et al.
Published: (2019-08-01)

Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature
by: Yong Zhang, et al.
Published: (2021-10-01)

A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer
by: Ying Jin, et al.
Published: (2022-11-01)

Combination of Anti-EGFR and Anti-VEGF Drugs for the Treatment of Previously Treated Metastatic Colorectal Cancer: A Case Report and Literature Review
by: Yong Li, et al.
Published: (2021-05-01)

Efficacy and safety of fruquintinib dose‐escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single‐arm, multicenter, phase II study
by: Sirui Tan, et al.
Published: (2023-12-01)

Case report: long-term sustained remission in a case of metastatic colon cancer with high microsatellite instability and KRAS exon 2 p.G12D mutation treated with fruquintinib after local radiotherapy: a case report and literature review
by: Ruiqi Wang, et al.
Published: (2023-06-01)

Fruquintinib inhibits the migration and invasion of colorectal cancer cells by modulating epithelial-mesenchymal transition via TGF-β/Smad signaling pathway
by: Qinqin Song, et al.
Published: (2025-03-01)

Efficacy and Safety of Fruquintinib‐Based Treatment in Patients with Refractory Bone and Soft Tissue Sarcoma after Developing Resistance to Several TKIs: A Multicenter Retrospective Study
by: Chenchen Yang, et al.
Published: (2024-10-01)

Efficacy and safety of radiotherapy combined with anti‐angiogenic therapy and immune checkpoint inhibitors in MSS/pMMR metastatic colorectal cancer
by: Menglan Zhai, et al.
Published: (2024-01-01)

Progress of Biomarkers to Predict Response to Immune Checkpoint Inhibitors in Microsatellite Stability Colorectal Cancer
by: WANG Zhiqiang, et al.
Published: (2023-02-01)

Editorial: Strategies in overcoming the chemoresistance in colorectal cancer
by: Sona Vodenkova, et al.
Published: (2023-10-01)

Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China
by: Miaomiao Gou, et al.
Published: (2022-07-01)

The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives
by: Annalice Gandini, et al.
Published: (2023-05-01)

Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer
by: Javier Ros, et al.
Published: (2023-02-01)

Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
by: Yanrong Wang, et al.
Published: (2025-03-01)

Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors
by: Tinglei Huang, et al.
Published: (2021-03-01)

A Case of Complete Remission in Proficient Mismatch Repair (pMMR) Advanced Colon Cancer Treated with Sintilimab and XELOX
by: Zhu J, et al.
Published: (2023-02-01)

Immunotherapy, Inflammation and Colorectal Cancer
by: Charles Robert Lichtenstern, et al.
Published: (2020-03-01)

Case Report: Multiple cutaneous keratoacanthoma-like lesions in a colorectal cancer patient treated with sintilimab
by: Shiyi Li, et al.
Published: (2025-03-01)

Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer
by: Yuwei Ding, et al.
Published: (2023-11-01)

IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarization
by: Lv Guangzhao, et al.
Published: (2025-01-01)